These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17875704)

  • 1. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.
    Tang B; Yoo N; Vu M; Mamura M; Nam JS; Ooshima A; Du Z; Desprez PY; Anver MR; Michalowska AM; Shih J; Parks WT; Wakefield LM
    Cancer Res; 2007 Sep; 67(18):8643-52. PubMed ID: 17875704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
    Busch S; Acar A; Magnusson Y; Gregersson P; Rydén L; Landberg G
    Oncogene; 2015 Jan; 34(1):27-38. PubMed ID: 24336330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
    Wilson CA; Cajulis EE; Green JL; Olsen TM; Chung YA; Damore MA; Dering J; Calzone FJ; Slamon DJ
    Breast Cancer Res; 2005; 7(6):R1058-79. PubMed ID: 16457687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.
    Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW
    Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast.
    Chakravarthy D; Green AR; Green VL; Kerin MJ; Speirs V
    Int J Oncol; 1999 Jul; 15(1):187-94. PubMed ID: 10375614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
    Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
    Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
    Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
    J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
    Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.
    Page JM; Merkel AR; Ruppender NS; Guo R; Dadwal UC; Cannonier S; Basu S; Guelcher SA; Sterling JA
    Biomaterials; 2015 Sep; 64():33-44. PubMed ID: 26115412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-beta receptor.
    Jung CW; Kim ES; Seol JG; Park WH; Lee SJ; Kim BK; Lee YY
    Leuk Res; 1999 Dec; 23(12):1105-12. PubMed ID: 10613355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
    Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM.
    Wang Y; Yu Y; Tsuyada A; Ren X; Wu X; Stubblefield K; Rankin-Gee EK; Wang SE
    Oncogene; 2011 Mar; 30(12):1470-80. PubMed ID: 21102523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development.
    Lagadec P; Raynal S; Lieubeau B; Onier N; Arnould L; Saint-Giorgio V; Lawrence DA; Jeannin JF
    Am J Pathol; 1999 Jun; 154(6):1867-76. PubMed ID: 10362813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
    Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
    Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.
    Bierie B; Chung CH; Parker JS; Stover DG; Cheng N; Chytil A; Aakre M; Shyr Y; Moses HL
    J Clin Invest; 2009 Jun; 119(6):1571-82. PubMed ID: 19451693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells.
    Ko Y; Koli KM; Banerji SS; Li W; Zborowska E; Willson JK; Brattain MG; Arteaga CL
    Int J Oncol; 1998 Jan; 12(1):87-94. PubMed ID: 9454891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer.
    Guo Y; Jacobs SC; Kyprianou N
    Int J Cancer; 1997 May; 71(4):573-9. PubMed ID: 9178810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.